October 23, 2022
PhaseBio Pharmaceuticals, Inc.
Case Number:
1:22-bk-10995
Court:
Nature of Suit:
Firms
- Armstrong Teasdale
- Bielli & Klauder
- Buchalter APC
- Buchanan Ingersoll
- Chipman Brown
- Cooley LLP
- Covington & Burling
- Goodwin Procter
- Ice Miller
- Keating Muething
- Klehr Harrison
- K&L Gates
- Lewis Brisbois
- Lowenstein Sandler
- Maron Marvel
- McCarter & English
- McDermott Will & Emery
- Miller & Martin
- Morris James
- O'Melveny & Myers
- Orrick Herrington
- Porzio Bromberg
- Potter Anderson
- Richards Layton
- Seyfarth Shaw
- Venable LLP
- Womble Bond
Companies
- Certara USA Inc.
- Chiesi Farmaceutici SpA
- KPMG International
- MedImmune LLC
- Miller Buckfire & Co. LLC
- Oracle Corp.
- PhaseBio Pharmaceuticals Inc.
- Synchrogenix
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
June 26, 2024
Pharma Co. PhaseBio Can Exit Ch. 11 With Wind-Down Plan
A Delaware bankruptcy judge on Wednesday gave her blessing for pharmaceutical developer PhaseBio Pharmaceuticals Inc. to liquidate its assets and wind down after settlement agreements with creditors and a business partner cleared a path for it to exit Chapter 11 after roughly 19 months.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login